**The impact of timing of renal replacement therapy on the outcome of acute kidney injury in critically ill patient: a meta-analysis**

Ahmed Elshaer, Rania Magdy Mohamed, Hany Magdy Fahim, Mahmoud Omar

Department of Anesthesiology and Intensive Care and Pain Management, Faculty of medicine, Aim Shams University, Egypt

Drmahmoudomar25@gmail.com

**Abstract: Background:** Acute kidney injury (AKI) is a common complication in the critically ill patients and associated with a substantial morbidity and mortality. Renal replacement therapy (RRT) remains the primary supportive management strategy for patients with severe AKI. However; the exact timing of initiation of RRT for better patient outcome is still debatable with conflicting data from randomized controlled trials. Thus, a systematic review and meta-analysis was performed to assess the impact of “early” versus “late” initiation of RRT. **Objectives:** To investigate the impact of timing of initiation of renal replacement therapy (RRT) on clinical outcomes in critically ill patients with acute kidney injury (AKI), focusing on the randomized controlled trials in this field. **Methods:** We enrolled 9 RCTs (since 2000 till 2019) with a total of 1636 patients in this Meta-analysis randomized as early and late groups focusing on mortality up to 90 days, intensive care unit LOS among survivors and non-survivors, hospital LOS among survivors and non-survivors, renal function recovery and renal replacement therapy dependence. The most fundamental differences among the trials were the large differences concerning the timing of RRT initiation among studies. Urine output, serum creatinine, serum urea nitrogen and AKI stages were not used unified in the individual studies to define the early and late RRT strategies. **Results:** A pooled analysis of the studies indicated no mortality benefit with “early” RRT, with an RR of 0.97 (95% CI 0.87 to 1.09, P = 0.010). There was no significant difference in intensive care unit (ICU) length of stay (LOS) or hospital LOS between the early and late RRT groups for survivors or non-survivors. Pooled analysis also demonstrated no significant change in renal function recovery (RR 0.99, 95% CI 0.91 to 1.07, I2 = 58.878%), RRT dependence (RR 0.76, 95% CI 0.42 to 1.37, I2 = 0%). **Conclusion**: Our meta-analysis revealed that the “early” initiation of RRT in critically ill patients did not result in a reduced Mortality. A pooled analysis of secondary outcomes Showed no significant difference in Intensive care unit Length of stay (LOS) or hospital Length of stay (LOS) between early and late RRT group for survivors or non- survivors. A pooled analysis also demonstrated no significant change in renal function recovery and RRT dependence.

[Ahmed Elshaer, Rania Magdy Mohamed, Hany Magdy Fahim, Mahmoud Omar. **The impact of timing of renal replacement therapy on the outcome of acute kidney injury in critically ill patient: a meta-analysis.** *N Y Sci J* 2019;12(8):7-18]. ISSN 1554-0200 (print); ISSN 2375-723X (online). <http://www.sciencepub.net/newyork>. 2. doi:[10.7537/marsnys120819.02](http://www.dx.doi.org/10.7537/marsnys120819.02).

**Key Words:** Acute kidney injury, renal replacement therapy, Length of stay

**1. Introduction:**

Acute kidney injury (AKI) is a common potentially life threatening complication of illnesses among 1% of the community-based population, 8–15% of hospitalized patients, and up to 50% of critically ill patients admitted to the intensive care unit (ICU) ***(1).***

AKI carries increased risk of morbidity and mortality and adds to the health- care cost, even in mild temporary form ***(2).***

Although renal replacement therapy (RRT) remains the primary supportive management strategy for patients with severe AKI, it could also be associated with complications and adverse events ***(3).***

Despite improvements in RRT technology, it is still not clear whether the outcome of patients with AKI who require RRT has improved over the years ***(4).***

Earlier initiation of RRT may provide a better control of fluid and electrolyte balance, superior acid–base homeostasis, removal of uremic waste, and prevention of subsequent complications attributable to AKI. Furthermore, earlier RRT could potentially limit the kidney-specific and remote organ injuries due to fluid overload, electrolyte imbalance, and systemic inflammation ***(5).***

However, earlier RRT may also expose the patients to increased risks of hemodynamic instability, anticoagulation induced bleeding, blood stream infection, and even inflammatory or oxidative stress induced by the bio-incompatibility of the dialyzer membranes.

In comparison, later initiation of RRT may allow more time for hemodynamic optimization prior to RRT, and it may avoid the need for RRT and its associated complications ***(6)***.

In recent decades, the timing of RRT initiation has been evaluated in different population types (e. g., surgical or medical patients). Variability in the definitions of AKI and RRT timing has resulted in contradicting conclusions among the various studies ***(7).***

Similarly, previous systematic analyses regarding the optimal timing of RRT initiation were unable to draw definitive conclusions owing to the scarcity of large-scale randomized controlled trials (RCTs), non-standardized triggers for RRT initiation, and heterogeneities of population and study design while the observational studies tended to show more beneficial effects for earlier RRT, clinical trials were unable to replicate these findings ***(8)***.

Recently, two large RCTs showed contradictory results and attracted considerable attention from both clinicians and researchers. The first was a multicenter RCT by the AKIKI study group, which showed no significant differences in 60-day mortality between early and delayed RRT groups ***(8)***.

Another was the ELAIN trial, ***(9)*** a single-center RCT that showed significant benefits in terms of 90-day mortality, renal function recovery, and hospital length of stay (LOS) among patients in the early RRT group. Although these two RCTs exhibited opposing results, they added value to the field of critical care ***(9)***.

This systematic review is conducted to include all relevant RCTs related to the impact of the timing of RRT initiation among critically ill patients with moderate to severe AKI.

**2. Patients and methods:**

**Studies and participants**

In the current meta-analysis, we searched for interventional clinical trials in critically ill adult patients evaluated to have Acute Kidney Injury.

**Search strategy for identification of the studies**

Electronic search was conducted in PubMed, Scopus, Google scholar and Cochrane library and then the relevant articles and studies were identified and obtained.

**Inclusion criteria were:**

1. Adult critically ill patient ≥ 18 years old.
2. Having acute kidney injury.
3. Randomized controlled trials.
4. Clearly comparing early versus late RRT initiation with effect on mortality and clinically relevant secondary outcomes.

**Exclusion criteria were:**

Between 23 studies 14 study were excluded for all the following measures:

* Not randomized controlled trials.
* Early and late RRT criteria are unclear.
* Lack of mortality data.
* Studies without clear comparison of the outcomes.

While the other 9 studies were included in the current meta-analysis as they fulfilled the inclusion criteria.

**Characteristics of the studies:**

**Table (1):** Basic Characteristics of Studies Included in Meta-analysis.

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Study** | **Country** | **Period** | **Study design** | **Duration of follow up (days)** | **Number of patients** |
| **Total** | **Early** | **Late** |
| **Bouman et al., 2002 (10)** | Netherland | 1998-2000 | Two center | 28 | 106 | 70 | 36 |
| **Durmaz et al.,2003 (11)** | Turkey | 1999–2001 | Single center | 30 | 44 | 21 | 23 |
| **Sugahara and suzuki,2004 (12)** | Japan | 1995–1997 | Single center | 14 | 28 | 14 | 14 |
| **Payen et al.,2009 (13)** | France | 1997-2000 | Multi center | 28 | 76 | 37 | 39 |
| **Jamale et al.,2013 (14)** | India | 2010–2012 | Single center | 90 | 208 | 102 | 106 |
| **Combes et al.,2015 (15)** | France | 2009–2012 | Multi center | 90 | 224 | 112 | 112 |
| **Wald et al.,2015 (16)** | Canada | 2012–2013 | Multi center | 90 | 100 | 48 | 52 |
| **Gaudry et al.,2016** | France | 2013–2016 | Multi center | 60 | 619 | 311 | 308 |
| **Zarbock et al.,2016** | Germany | 2013–2015 | Single center | 90 | 231 | 112 | 119 |

**Table (2):** Age and sex among the included studies

|  |  |  |  |
| --- | --- | --- | --- |
| **Study** | **Total** | **Mean age (years)** | **Male %** |
| **Early** | **Late** | **Early** | **Late** |
| **Bouman et al., 2002** | 106 | 68 | 67 | 57 | 61 |
| **Durmaz et al.,2003** | 44 | 58 | 54 | 76 | 83 |
| **Sugahara and suzuki,2004** | 28 | 65 | 64 | 64 | 64 |
| **Payen et al.,2009** | 76 | 58 | 59 | 73 | 69 |
| **Jamale et al.,2013** | 208 | 43 | 42 | 61 | 75 |
| **Combes et al.,2015** | 224 | 61 | 58 | 79 | 80 |
| **Wald et al.,2015** | 100 | 62 | 64 | 73 | 71 |
| **Gaudry et al.,2016** | 619 | 65 | 67 | 67 | 64 |
| **Zarbock et al.,2016** | 231 | 66 | 68 | 70 | 57 |

A total of 1636 patients were enrolled. Of these studies, four of the studies were multi-center studies ***(Payen et al., 2009- Combes et al., 2015- Wald et al., 2015- Guadry et al., 2016).***

Four were single-center studies ***(Durmaz et al., 2003- Sugahara and suzuki,2004- Jamale et al., 2013- Zarbock et al., 2016),*** and one was a two-center study ***(Bouman et al., 2002).***

Three studies examined only patients following cardiac surgery ***(Durmaz et al., 2003- Sugahara and suzuki,2004-Combes et al., 2015)****,* whereas the remaining six studies were mixed with medical or surgical patients.

The follow-up time reported in these studies ranged from 14 to 90 days **(table 1)**. Age and sex are demonstrated in **(table 2).**

The definition of early and late initiation of RRT for each specific study is outlined in **(Table 3).**

**Table (3):** Definition of Early and Late RRT in Studies Included in the Meta-analysis

|  |  |  |  |
| --- | --- | --- | --- |
| **Author** | **Early criteria** | **Late criteria** | **MODALITY** |
| Bouman2002 | RRT within 12 h if urine output <30 ml/h, Cr clearance <20 ml/min, and mechanical ventilation | Urea > 40 mmol/L or K > 6.5 mmol/L or severe pulmonary edema | CVVH |
| Durmaz 2003 | Preoperative prophylactic RRT in all patients and postoperative s Cr increased >10% | Postoperative sCr increased >50% or urine output <400 ml/24 h | IHD |
| Sugahara and suzuki,2004 | Urine output <30 ml/h for 3 h or urine output <750 ml/day | Urine output <20 ml/h for 2 h or urine output <500 ml/day | CVVH |
| Payen2009 | RRT for 96-h period within 24 h of diagnosis of severe sepsis | Classic indications for RRT (azotemia, fluid overload, acidosis, and hyperkalemia) | CVVH |
| Jamale2013 | Serum urea nitrogen >70 mg/dL and/or creatinine>7 mg/dL | Classic indications for RRT or Uremic nausea and anorexia | IHD |
| Combes2015 | RRT within 24 h of diagnosis of post-cardiac surgery shock | Creatinine>4 mg/dL or preoperative creatinine × 3 or UOP<0.3 ml/kg/h /24 h or urea >36 mmol/L or life-threatening hyperkalemia | CVVH |
| Wald2015 | sCr increased >200%, urine output <6 ml/kgwithin 12 h, or NGAL ≥ 400 ng/ml | K > 6.0 mmol/L or serum bicarbonate <10 mmol/L or pulmonaryEdema | IHD/CVVH/SLEDD |
| Gaudry2016 | RRT within 6 h of diagnosis of KDIGO stage 3 | K > 6.0 mmol/L or PH < 7.15 or pulmonary edema or blood ureanitrogen >112 mg/dL or oliguria >72 h | IHD/CVVH |
| Zarbock2016 | RRT within 8 h of diagnosis of KDIGO stage 2 | RRT within 12 h of KDIGO stage 3 or no RRT | CVVH |

Five studies used urine output and/or serum creatinine or serum urea nitrogen or creatinine clearance for defining early and late RRT ***(Wald et al., 2015-Durmaz et al., 2003-Sugahara and suzuki,2004-Jamale et al., 2013-Bouman et al., 2002)****,* two studies started early RRT with diagnosis of severe sepsis or post-cardiac surgery shock ***(Payen et al., 2009-Combes et al., 2015)*** and the latest two studies in 2016 used Kidney Disease: Improving Global Outcomes (KIDGO) stage 2 or stage 3 to define early RRT ***(Gaudry et al., 2016-Zarbock et al., 2016).***

In most of the studies, late RRT was defined as a classic indication, including azotemia, oliguria, pulmonary edema, hyperkalemia and metabolic acidosis. The individual studies defined early and late RRT by using variable cutoff values in serum creatinine or urine output **(table 3).**

**Interventions**:

In the current meta-analysis, we considered all studies reporting the timing of renal replacement therapy early versus late in all medical and surgical patients. The modality of RRT varied significantly among the individual studies **(table 3)**.

The modality of continuous vena-venous hemofiltration (CVVH) was used in five studies ***(Bouman et al., 2002-Sugahara and suzuki,2004-Payen et al., 2009-Combes et al., 2015 and Zarbock et al., 2016)*** and intermittent hemodialysis (IHD) was used in two studies ***(Durmaz et al., 2003 and Jamale et al., 2013)****.* In the remaining two studies, some of the patients received CVVH modality, and the others received IHD or sustained low-efficiency dialysis (SLED) modality ***(Guadry et al., 2016 and wald et al., 2015).***

***Outcome measures:***

The primary outcome was

1. Mortality, Including 14-day mortality, 28-day mortality, 30-day mortality, 60-day mortality, 90-day mortality, ICU mortality, and in-hospital mortality. The longest follow-up mortality reported in the individual studies was extracted for the pooling analysis.

Secondary outcomes included

1. The ICU length of stay (LOS) in survivors and non survivors
2. Hospital LOS in survivors and non survivors
3. Renal function recovery
4. Renal replacement therapy dependence.

**Study selection:**

One reviewer (MO) checked all identified titles and abstracts and other reviewer (HM) validated this check. The 2 reviewers examined all potential trials and graded their methodological quality. Any disagreement within or between reviewers was resolved by discussion with each other.

**Data extraction:**

One reviewer (MO) drew up a standard data extraction form and other reviewer (HM) validated it.

**Statistical Methods for Meta-Analysis:**

Meta-analysis was performed using Comprehensive Meta-Analysis version 3.0 software. In case of quantitative outcomes Mean±SD and total sample count were collected then the mean differences were pooled to calculate the weighted mean, while in case of qualitative outcomes, events and total sample count were collected then the relative rates were pooled to calculate the weighted relative rate. Forest plots were used to present the individual and weighted estimates. Heterogeneity (I2) index was calculated to test variation of pooled estimates for each outcome, and presented by Funnel plot. The level of significance was taken at P value < 0.050 is significant, otherwise is non-significant.

**3. Results:**

***Primary outcome:***

1-Mortality

Table (4) and figure (1,2) show that: The mortality was reported in the nine included studies. There was significant heterogeneity among these studies. Thus, we performed the statistics using a random-effects model, and the results showed that mortality was not significantly different between early and late interventions.

**Table (4):** Meta-analysis for mortality.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Study** | **Early****(event/total)** | **Late****(event/total)** | **RR****(95% CI)** | **P** |
| **Total** | **N** | **%** | **Total** | **N** | **%** |
| **Bouman et al., 2002** | 70 | 31 | 44.3 | 36 | 14 | 38.9 | 1.14 (0.70–1.85) | 0.601 |
| **Durmaz et al., 2003** | 21 | 1 | 4.8 | 23 | 7 | 30.4 | 0.16 (0.02–1.17) | 0.070 |
| **Sugahara and suzuki,2004** | 14 | 2 | 14.3 | 14 | 12 | 85.7 | 0.17 (0.05–0.61) | **0.007\*** |
| **Payen et al., 2009** | 37 | 20 | 54.1 | 39 | 17 | 43.6 | 1.24 (0.78–1.97) | 0.364 |
| **Jamale et al., 2013** | 102 | 21 | 20.6 | 106 | 13 | 12.3 | 1.68 (0.89–3.17) | 0.110 |
| **Wald et al., 2015** | 48 | 18 | 37.5 | 52 | 19 | 36.5 | 1.03 (0.62–1.71) | 0.921 |
| **Combes et al.,2015** | 112 | 51 | 45.5 | 112 | 44 | 39.3 | 1.16 (0.85–1.58) | 0.345 |
| **Gaudry et al., 2016** | 311 | 150 | 48.2 | 308 | 153 | 49.7 | 0.97 (0.83–1.14) | 0.719 |
| **Zarbock et al., 2016** | 112 | 44 | 39.3 | 119 | 65 | 54.6 | 0.72 (0.54–0.95) | **0.022\*** |
| **Overall effect** | -- | -- | 0.97 (0.87–1.09) | 0.611 (z=0.509) |
| **Heterogeneity** | **I2** | 60.405 | **P** | **0.010\*** |

RR: Relative rate, CI: Confidence interval, \*Significant



**Figure (1):** Forest plot for mortality



**Figure (2):** Funnel plot for mortality

**Secondary outcomes**:

2- ICU length of stay.

**Survivors**

Table (5) and figures (3,4) show that: ICU stay among survivors was reported in the four included studies. There was no significant heterogeneity among these studies. Thus, we performed the statistics using a fixed-effects model, and the results showed that ICU stay among survivors was not significantly different between early and late interventions.

**Table (5):** Meta-analysis for ICU stay (days) among survivors.

| **Study** | **Effects** | **Difference** | **P** |
| --- | --- | --- | --- |
| **Early** | **Late** |
| **N** | **Mean±SD** | **N** | **Mean±SD** | **Mean±SE** | **95%CI** |
| **Bouman et al., 2002** | 47 | 10.9±19.9 | 26 | 15.0±10.7 | -4.1±4.2 | -12.4–4.2 | 0.330 |
| **Wald et al.,2015** | 30 | 11.0±15.9 | 33 | 13.5±17.8 | -2.5±4.3 | -10.9–5.9 | 0.558 |
| **Combes et al.,2015** | 63 | 13.0±13.3 | 69 | 13.0±15.6 | 0.0±2.5 | -5.0–5.0 | 1.000 |
| **Gaudry et al.,2016** | 161 | 13.0±11.1 | 155 | 13.0±11.9 | 0.0±1.3 | -2.5–2.5 | 1.000 |
| **Overall effect** | -0.4±1.1 | -2.5–1.7 | 0.692(z=0.396) |
| **Heterogeneity** | **I2** | 0.000 | **P** | 0.799 |

RR: Relative rate, CI: Confidence interval, \*Significant



**Figure (3):** Forest plot for ICU stay among survivors



**Figure (4):** Funnel plot for ICU stay among survivors

**Non Survivors**

Table (6) and figure (5) show that: ICU stay among non-survivors was reported in the two included studies. There was no significant heterogeneity among these studies. Thus, we performed the statistics using a fixed-effects model, and the results showed that ICU stay among non-survivors was not significantly different between early and late interventions.

**Table (6):** Meta-analysis for ICU stay (days) among non-survivors.

|  |  |  |  |
| --- | --- | --- | --- |
| **Study** | **Effects** | **Difference** | **P** |
| **Early** | **Late** |
| **N** | **Mean±SD** | **N** | **Mean±SD** | **Mean±SE** | **95%CI** |
| **Combes et al.,2015** | 49 | 11.0±14.1 | 44 | 6.0±8.9 | -5.0±2.5 | -9.9–-0.1 | **0.044\*** |
| **Gaudry et al.,2016** | 150 | 6.0±8.9 | 153 | 6.0±8.1 | 0.0±1.0 | -1.9–1.9 | 1.000 |
| **Overall effect in increasing survival duration** | -0.7±0.9 | -2.5–1.1 | **0.459 (z=0.741)** |
| **Heterogeneity** | **I2** | **71.628** | **P** | 0.060 |

RR: Relative rate, CI: confidence interval, \*Significant

Funnel plot for ICU stay among non-survivors could not be performed as the included studied were less than three.



**Figure (5):** Forest plot for ICU stay among non-survivors

**3- Hospital length of stay.**

**Survivors**

Table (7) and figures (6,7) show that: Hospital stay among survivors was reported in the four included studies. There was no significant heterogeneity among these studies. Thus, we performed the statistics using a fixed-effects model, and the results showed that hospital stay among survivors was not significantly different between early and late interventions.

**Table (7):** Meta-analysis for hospital stay (days) among survivors.

|  |  |  |  |
| --- | --- | --- | --- |
| **Study** | **Effects** | **Difference** | **P** |
| **Early** | **Late** |
| **Total** | **Mean±SD** | **Total** | **Mean±SD** | **Mean±SE** | **95%CI** |
| **Bouman et al., 2002** | 47 | 32.7±35.7 | 26 | 42±30.1 | -9.3±8.3 | -25.5–6.9 | 0.261 |
| **Wald et al., 2015** | 30 | 29.0±21.5 | 33 | 31.0±23 | -2.0±5.6 | -13.0–9.0 | 0.722 |
| **Combes et al., 2015** | 62 | 37.0±23.7 | 68 | 29.0±21.5 | 8.0±4.0 | 0.2–15.8 | **0.044\*** |
| **Gaudry et al., 2016** | 161 | 29.0±25.2 | 155 | 32.0±23 | -3.0±2.7 | -8.3–2.3 | 0.270 |
| **Overall effect** | -0.4±2.0 | -4.4–3.6 | **0.846 (z=0.195)** |
| **Heterogeneity** | **I2** | 54.853 | **P** | 0.084 |

RR: Relative rate, CI: Confidence interval, \*Significant



**Figure (6):** Forest plot for hospital stay among survivors



**Figure (7):** Funnel plot for ICU stay among survivors

Table (8) and figure (8) show that: Hospital stay among non-survivors was reported in the two included studies. There was no significant heterogeneity among these studies. Thus, we performed the statistics using a fixed-effects model, and the results showed that hospital stay among non-survivors was not significantly different between early and late interventions.

**Table (8):** Meta-analysis for hospital stay (days) among non-survivors.

|  |  |  |  |
| --- | --- | --- | --- |
| **Study** | **Effects** | **Difference** | **P** |
| **Early** | **Late** |
| **Total** | **Mean±SD** | **Total** | **Mean±SD** | **Mean±SE** | **95%CI** |
| **Combes et al., 2015** | 50 | 11.0±14.8 | 44 | 6.0±8.9 | -5.0±2.6 | -10.0–0.0 | 0.051 |
| **Gaudry et al., 2016** | 150 | 6.0±8.9 | 153 | 6.0±8.1 | 0.0±1.0 | -1.9–1.9 | 1.000 |
| **Overall effect** | -0.6±0.9 | -2.4–1.2 | **0.487 (z=0.695)** |
| **Heterogeneity** | **I2** | **69.913** | **P** | 0.069 |

RR: Relative rate, CI: Confidence interval, \*Significant



**Figure (8):** Forest plot for hospital stay among non-survivors

Funnel plot for hospital stay among non-survivors could not be performed as the included studied were less than three.

**4-Renal function recovery**

Table (9) and figure (9,10) show that: Renal function recovery was reported in the seven included studies. There was significant heterogeneity among these studies. Thus, we performed the statistics using a random-effects model, and the results showed that renal function recovery was not significantly different between early and late interventions.

**Table (9):** Meta-analysis for renal function recovery.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Study** | **Early (event/total)** | **Late (event/total)** | **RR (95% CI)** | **P** |
| **Total** | **N** | **%** | **Total** | **N** | **%** |
| **Bouman et al., 2002** | 70 | 39 | 55.7 | 36 | 22 | 61.1 | 0.91 (0.65–1.27) | 0.587 |
| **Sugahara and suzuki,2004** | 14 | 10 | 71.4 | 14 | 2 | 14.3 | 5.00 (1.33–18.81) | **0.017\*** |
| **Jamale et al.,2013** | 102 | 76 | 74.5 | 106 | 88 | 83.0 | 0.90 (0.78–1.03) | 0.137 |
| **Wald et al.,2015** | 112 | 61 | 54.5 | 112 | 69 | 61.6 | 0.88 (0.71–1.11) | 0.280 |
| **Combes et al.,2015** | 48 | 30 | 62.5 | 52 | 31 | 59.6 | 1.05 (0.77–1.43) | 0.767 |
| **Gaudry et al.,2016** | 311 | 154 | 49.5 | 308 | 147 | 47.7 | 1.04 (0.88–1.22) | 0.656 |
| **Zarbock et al.,2016** | 112 | 60 | 53.6 | 119 | 46 | 38.7 | 1.39 (1.04–1.84) | **0.025\*** |
| **Overall effect** | -- | -- | 0.99 (0.91–1.07) | 0.767 (z=0.297) |
| **Heterogeneity** | **I2** | 58.878 | **P** | **0.024\*** |

RR: Relative rate, CI: Confidence interval, \*Significant



**Figure (9):** Forest plot for renal function recovery



**Figure (10):** Funnel plot for renal function recovery

**5- Renal Replacement Therapy Dependence.**

Table (10) and figure (11, 12) show that: Renal replacement therapy dependence was reported in the six included studies. There was no significant heterogeneity among these studies. Thus, we performed the statistics using a fixed-effects model, and the results showed that renal replacement therapy dependence was not significantly different between early and late interventions.

**Table (10):** Meta-analysis for renal replacement therapy dependence.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Study** | **early****(event/total)** | **Late****(event/total)** | **RR****(95% CI)** | **P** |
| **Total** | **N** | **%** | **Total** | **N** | **%** |
| **Bouman et al., 2002** | 39 | 1 | 2.6 | 22 | 0 | 0.0 | 1.73 (0.07–40.63) | 0.735 |
| **Sugahara and suzuki,2004** | 12 | 2 | 16.7 | 2 | 0 | 0.0 | 1.15 (0.07–18.32) | 0.919 |
| **Jamale et al., 2013** | 102 | 5 | 4.9 | 106 | 5 | 4.7 | 1.04 (0.31–3.48) | 0.950 |
| **Wald et al., 2015** | 30 | 0 | 0.0 | 33 | 2 | 6.1 | 0.22 (0.01–4.39) | 0.321 |
| **Gaudry et al., 2016** | 157 | 3 | 1.9 | 155 | 8 | 5.2 | 0.37 (0.10–1.37) | 0.137 |
| **Zarbock et al., 2016** | 67 | 9 | 13.4 | 53 | 8 | 15.1 | 0.89 (0.37–2.15) | 0.795 |
| **Overall effect** | -- | -- | 0.76 (0.42–1.37) | 0.357 (z=0.921) |
| **Heterogeneity** | **I2** | 0.000 | **P** | 0.769 |

RR: Relative rate, CI: Confidence interval, \*Significant



**Figure (11):** Forest plot for renal replacement therapy dependence



**Figure (12):** Funnel plot for renal replacement therapy dependence

**4. Discussion:**

We enrolled 9 RCTs with a total of 1636 patients in this Meta-analysis and found that “early” RRT had no beneficial effect on mortality of patients with AKI compared with “Late” RRT. Furthermore, pooled analysis of these studies also showed no significant benefit of early RRT in Intensive care unit length of stay among survivors and non-survivors, hospital length of stay among survivors and non-survivors, renal function recovery and RRT dependence.

It has been known that there are many differences between after-cardiac surgery patients and those with no cardiac surgery, especially on the perioperative hemodynamic management.

However, subgroup analysis of the studies concerning the patients post cardiac surgery or those with non-cardiac surgery did not reveal a survival benefit of early RRT intervention.

In addition, the conclusion remained the same; regardless of whether early was defined by AKI stages according to the KDIGO classification (17) or on the basis of urine output or serum creatinine.

One highlight of this meta-analysis was that we included two new large RCTs ***(Gaudry et al., 2016-Zarbock et al., 2016)****,* which made our results more convincing.

Second, survivors and non-survivors were analyzed separately in the secondary outcome analysis, and the same conclusion was reached.

The most fundamental differences among the trials were the large differences concerning the timing of RRT initiation among studies. Urine output, serum creatinine, serum urea nitrogen and AKI stages were not used unified in the individual studies to define the early and late RRT strategies.

In extreme cases, patients in the early RRT group in one study might be enrolled as late RRT in other studies. The high heterogeneity of definitions of “early” and “late” RRT between RCTs prevented the establishment of definitive conclusions.

Second most studies enrolled AKI patients with a mixed population, whereas the optimal timing of RRT initiation might be associated with the primary diseases.

Moreover, the severity of the primary disease, presence of comorbid conditions, complications after surgery and fluid balance before RRT initiation could also be the possible confounders related to study outcome.

Additionally, we cannot omit the progression of the critical care medicine during the past decade. In the study conducted in patients with acute renal failure following coronary bypass surgery in 2004, the mortality was as high as 86% in the “late” group ***(Sugahara et al., 2004)****.* However, the other study, conducted in post-cardiac surgery shock patients in 2015, showed that the 30-day mortality of the “early” and “late” group was only 36% ***(Combes et al., 2015)****.*

We found that most of the RCTs published over the past decade failed to prove the benefit of early initiation of RRT. Great progress in hemodynamic monitoring, mechanical ventilation, nutrition support and even RRT technology development has been achieved in critical care medicine in the past decade.

Therefore, studies published before 2000 were excluded in this meta-analysis.

Also, The AKIKI study claimed that up to 49% of the patients in the delayed-strategy group avoided receiving RRT ***(Gaudry et al., 2016),*** The Elian trial gave opposing results *(****Zarbock et al.,2016).***

However, we cannot accurately predict the needs for RRT or opportunity of renal recovery in critically ill patients in the retrospective studies.

So we reached this overall conclusion.

**Conclusions**

Our meta-analysis revealed that the “early” initiation of RRT in critically ill patients did not result in a reduced Mortality.

A pooled analysis of secondary outcomes Showed no significant difference in Intensive care unit Length of stay (LOS) or hospital Length of stay (LOS) between early and late RRT group for survivors or non- survivors.

A pooled analysis also demonstrated no significant change in renal function recovery and RRT dependence.

**References**:

1. Clark E, Wald R, Walsh M, Bagshaw SM. Timing of initiation of renal replacement therapy for acute kidney injury: a survey of nephrologists and intensivists in Canada. Nephrol Dial Transpl. 2012;27:2761–7.
2. Pannu N, James M, Hemmelgarn B, Klarenbach S. Association between AKI, recovery of renal function, and long‑term outcomes after hospital discharge. Clin J Am SocNephrol. 2013;8:194–202.
3. Schneider AG, Bellomo R, Bagshaw SM, Glassford NJ, Lo S, Jun M, et al. Choice of renal replacement therapy modality and dialysis dependence after acute kidney injury: a systematic review and meta‑analysis. Intensive Care Med. 2013; 39:987–97.
4. Akhoundi A, Singh B, Vela M, Chaudhary S, Monaghan M, Wilson GA, et al. Incidence of adverse events during continuous renal replacement therapy. Blood Purif. 2015;39:333–9.
5. Wald R, Bagshaw SM. The timing of renal replacement therapy initiation in acute kidney injury: is earlier truly better? Crit Care Med. 2014;42:1933–4.
6. Shingarev R, Wille K, Tolwani A. Management of complications in renal replacement therapy. Semin Dial. 2013;24:164–8.
7. Carl DE, Grossman C, Behnke M, Sessler CN, Gehr TWB. Effect of timing of dialysis on mortality in critically ill, septic patients with acute renal failure. Hemodial Int. 2010;14:11–7.
8. Gaudry S, Hajage D, Schortgen F, Martin‑Lefevre L, Pons B, Boulet E, et al. Initiation strategies for renal‑replacement therapy in the intensive care unit. N Eng J Med. 2016;375:122–33.
9. Zarbock A, Kellum JA, Schmidt C, Van Aken H, Wempe C, Pavenstädt H, et al. Effect of early vs delayed initiation of renal replacement therapy on mortality in critically ill patients with acute kidney injury: The ELAIN Randomized Clinical Trial. JAMA. 2016;315:2190–9.
10. Bouman CS, Oudemans-Van Straaten HM, Tijssen JG, et al. Effects of early high volume continuous venovenous hemofiltration on survival and recovery of renal function in intensive care patients with acute renal failure: a prospective, randomized trial. Crit Care Med 2002; 30: 2205–11.
11. *Durmaz I, Yagdi T, Calkavur T, Mahmudov R, Apaydin AZ, Posacioglu H, Atay Y, Engin C*. Prophylactic dialysis in patients with renal dysfunction undergoing on-pump coronary artery bypass surgery. Ann Thorac Surg.2003;75(3):859–64.
12. *Sugahara S, Suzuki H*. Early start on continuous hemodialysis therapy improves survival rate in patients with acute renal failure following coronary bypass surgery. Hemodial Int. 2004; 8(4):320–5.
13. Payen D, Mateo J, Cavaillon JM, Fraisse F, Floriot C, Vicaut E. Impact of continuous Venovenous hemofiltration on organ failure during the early phase of severe sepsis: a randomized controlled trial. Crit Care Med. 2009;37(3):803–10.
14. Jamale Te, Nk H, Kulkarni M, Pradeep KJ, Keskar V, Jawale S, Mahajan D. Earlier-start versus usual-start dialysis in patients with community-acquired acute kidney injury: a randomized controlled trial. Am J Kidney Dis. 2013; 62(6):1116–21.
15. Combes A, Brechot N, Amour J, Cozic N, Lebreton G, Guidon C, Zogheib E, Thiranos JC, Rigal JC, Bastien O, et al. Early high-volume hemofiltration versus standard care for post-cardiac surgery shock. The Heroics study. Am J Respir Crit Care Med. 2015; 192(10):1179–90.
16. Wald R, Adhikari NK, Om S, Ma W, Pope K, Cohen A, Thorpe K, Mcintyre L, Lamontagne F, Soth M, et al. Comparison of standard and accelerated initiation of renal replacement therapy in acute kidney injury. Kidney Int.2015;88(4):897–904.
17. KDIGO clinical practice guideline for acute kidney injury. Kidney Int. 2012; Suppl. 1:1---138.

7/24/2019